Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - First Line Immunotherapy for Advanced Non Small Cell Lung Cancer NSCLC
Thu, 06/29/2017 - 06:00
Author
Luis Raez, MD FACP FCCP, Faculty, Board Member
Image

 

 

We welcome Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University with 2017 updates to our Lung Cancer Video Library.  In this recent video for GRACE, Dr. Raez discusses First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer NSCLC.

 


 

TRANSCRIPTS 
download here
 

 Dr. Luis Raez, MD FACP FCCP

Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute
Clinical Associate Professor of Medicine, Florida International University
 

These are very exciting times because we have recently moved immunotherapy to first line, meaning new patients with stage IV non-small cell lung cancer or metastatic patients.   Until recently immunotherapy was approved first for second line and based on some studies - very important - but immunotherapy, after that moved to the front line, so that new patients can have an opportunity to be treated.  Specifically, the Pembrolizumab was moved to the front line based on a study in which the Pembrolizumab was compared against chemotherapy, Carboplatin combination that are the standard of care so far and Pembrolizumab was able to give better outcomes than the combination or amalgamation of chemotherapy but the most important thing in this news is that we are developing markers to try to discover which patients will respond to immunotherapy and which ones will not.  The specific marker that probably everyone knows or cares about is PD-L1.  In this specific study, the patients will benefit from immunotherapy for new patients if the PD-L1 expression in the tumor, we are checking in the tumor, is more than 50%.  Immunotherapy front line was not approved for everybody, it was approved for this specific niche of patient that they will benefit.  The rest of the patients will still need to get chemotherapy or target therapy based on molecular markers if they have any of these genetic alterations that we reference all the time, EGFR, ALK, ROS1.  We only had one drug approved because unfortunately the other drug, Nivolumab, is already approved for second line.  In a similar study, Nivolumab was much against chemotherapy and Nivolumab was unable to get a better progression free survival than the patients on chemotherapy.  For that reason, we only have as a single agent so far, Pembrolizumab, approved in first line.  Of course, there will be changes because we have other immunotherapy agents coming to the market soon and new studies coming soon but so far Pembrolizumab is only approved as a single agent in the front line.  

 


  

Video Language

Next Previous link

Previous PostNext Post

Related Content

Community Forum

Hi Carole, Welcome to Grace. If the adrenal is the only place that cancer has been seen since your lobectomy it could be that it's what's known as a precocious metastasis/oligoprogression...

Carole,

These approaches haven't been directly compared, and it really depends on who can do the job and what they say is appropriate to expect in terms of side effects. In...

Hi CDaniele,
Welcome to Grace. If the TKI is working except for one or 2 places local treatment such as radiation can be used to get rid of the resistant cells...

I forgot to tell you that Grace is having its annual OncTalk live forum online Saturday, Dec. 11 at 8 am Pacific and 11 am Eastern
It will be invaluable to...

This is indeed a happy Thanksgiving in our house. I'll post about it at soon but we've just come out of a dark place and are feeling so hopeful today.
As...

Janine I am so happy to hear things like this. What you can or feel comfortable sharing, know that we are here! You are a very important part of the GRACE...

Hi and welcome to Grace.  I'm sorry your sister-in-law is going through this it's so unsettling, to say the least.  Cancer travels through the lymph system but also through blood vessels. ...

Recent Comments

JOIN THE CONVERSATION
Carole,These approaches…
By Dr West on Thu, 12/02/2021 - 20:49
Happy!
By dbrock on Thu, 12/02/2021 - 15:32
Hi Carole, Welcome to Grace…
By Dr West on Thu, 12/02/2021 - 13:22
Bump
By JanineT Forum … on Wed, 12/01/2021 - 10:24